CAI
Clinical Asset Index
by VOS Supply Group
Drugs · acquisition-cost intelligence

CELEBREX

celecoxib· ingredient celecoxibCoxibs· CELECOXIB 100 mg/1; CELECOXIB 200 mg/1; CELECOXIB 400 mg/1; CELECOXIB 50 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$0.08353
NADAC — pharmacy acquisition cost, not a retail/cash price

Acquisition-cost history

Weekly NADAC per EA — the trend nobody else shows. 8 weeks.

2025-03-192026-05-20

Medicare Part D coverage · CY2026

On 328 plan formularies · typical tier 2
Prior auth 0% · Step therapy 1% · Quantity limit 73% of formularies

Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.